Method
Level · gp.fundamentals.capex_revenue_ratio
Raw value 0.00% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTCue Biopharma, Inc.'s latest supported as-filed period reports revenue of $7.9M, 166.7% above the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.capex_revenue_ratio
Raw value 0.00% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -368.21% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 166.66% · CORE
Level · gp.fundamentals.operating_margin
Raw value -1113.30% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 622.15% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 302.63% · OPTIONAL
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 3 independently calculated changes: Revenue increased 166.7%; Operating margin moved 82099 bp lower; Operating income changed across a low base.
3 evidence-backed componentsOperating income changed -915.6% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes. Relative percentage is de-emphasized because the comparison has a low base. This reverses 4 consecutive comparable moves in the opposite direction.
Each point keeps the date investors could first observe it and its accession.
CUE · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0002059447-26-000006SEC ↗4/AAug 28, 2026Period Jul 9, 20260001974756-26-000006SEC ↗4Aug 17, 2026Period Aug 13, 20260001579629-26-000008SEC ↗4Aug 17, 2026Period Aug 13, 20260002138368-26-000007SEC ↗4Aug 14, 2026Period Aug 12, 20260001725092-26-000013SEC ↗10-QAug 14, 2026Period Jun 30, 20260001193125-26-352128SEC ↗8-KAug 14, 2026Period Aug 14, 20260001193125-26-352126SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 13, 2026Filed Aug 17, 2026 | Ray SumitaChief Legal Compliance Officer | Open Market SaleDirect | 6,442 | $30 | $195,515 | Form 4 ↗ |
| Aug 13, 2026Filed Aug 17, 2026 | Ray SumitaChief Legal Compliance Officer | Option ExerciseDirect | 18,196 | $0 | $0 | Form 4 ↗ |
| Aug 13, 2026Filed Aug 17, 2026 | Meluzio Michael VincentVP, Prin. Accounting Officer | Open Market SaleDirect | 3 | $31 | $93 | Form 4 ↗ |
| Aug 13, 2026Filed Aug 17, 2026 | Meluzio Michael VincentVP, Prin. Accounting Officer | Option ExerciseDirect | 13,647 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Operating margin changed -82099 basis points from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes. This reverses 4 consecutive comparable moves in the opposite direction.
Research & development changed +519.6% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Net income changed -1704.6% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes. Relative percentage is de-emphasized because the comparison has a low base. This reverses 4 consecutive comparable moves in the opposite direction.
Stock-based compensation changed +1787.4% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes. Relative percentage is de-emphasized because the comparison has a low base. This reverses 4 consecutive comparable moves in the opposite direction.
SBC / revenue changed +25987 basis points from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes. This reverses 4 consecutive comparable moves in the opposite direction.
Revenue changed +166.7% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-330730| Aug 13, 2026Filed Aug 17, 2026 |
| Ray SumitaChief Legal Compliance Officer |
| Open Market SaleDirect |
| 2,383 |
| $29 |
| $69,989 |
| Form 4 ↗ |
| Aug 13, 2026Filed Aug 17, 2026 | Ray SumitaChief Legal Compliance Officer | Open Market SaleDirect | 4 | $31 | $125 | Form 4 ↗ |
| Aug 13, 2026Filed Aug 17, 2026 | Ray SumitaChief Legal Compliance Officer | Option ExerciseDirect | 18,196 | $0 | $0 | Form 4 ↗ |
| Aug 13, 2026Filed Aug 17, 2026 | Meluzio Michael VincentVP, Prin. Accounting Officer | Option ExerciseDirect | 13,647 | $0 | $0 | Form 4 ↗ |
| Aug 13, 2026Filed Aug 17, 2026 | Meluzio Michael VincentVP, Prin. Accounting Officer | Open Market SaleDirect | 1,519 | $29 | $44,613 | Form 4 ↗ |
| Aug 13, 2026Filed Aug 17, 2026 | Meluzio Michael VincentVP, Prin. Accounting Officer | Open Market SaleDirect | 4,106 | $30 | $124,617 | Form 4 ↗ |
| Aug 13, 2026Filed Aug 14, 2026 | Lin Shao-LeeChief Executive Officer | Open Market SaleDirect | 5,423 | $27 | $147,451 | Form 4 ↗ |
| Aug 13, 2026Filed Aug 14, 2026 | Lin Shao-LeeChief Executive Officer | Open Market SaleDirect | 10,460 | $29 | $308,361 | Form 4 ↗ |
| Aug 13, 2026Filed Aug 14, 2026 | Lin Shao-LeeChief Executive Officer | Open Market SaleDirect | 2,375 | $28 | $66,761 | Form 4 ↗ |
| Aug 12, 2026Filed Aug 14, 2026 | Lin Shao-LeeChief Executive Officer | Open Market SaleDirect | 5,775 | $28 | $160,256 | Form 4 ↗ |
| Aug 12, 2026Filed Aug 14, 2026 | Lin Shao-LeeChief Executive Officer | Option ExerciseDirect | 109,179 | $0 | $0 | Form 4 ↗ |
| Aug 12, 2026Filed Aug 14, 2026 | Lin Shao-LeeChief Executive Officer | Open Market SaleDirect | 34,225 | $27 | $923,733 | Form 4 ↗ |
| Aug 12, 2026Filed Aug 14, 2026 | Lin Shao-LeeChief Executive Officer | Option ExerciseDirect | 109,179 | $0 | $0 | Form 4 ↗ |
| Jul 30, 2026Filed Aug 3, 2026 | Ahlers James MChief Financial Officer | Grant Or AwardDirect | 25,500 | $0 | $0 | Form 4 ↗ |
| Jul 30, 2026Filed Aug 3, 2026 | Ahlers James MChief Financial Officer | Grant Or AwardDirect | 51,000 | $0 | $0 | Form 4 ↗ |
| Jul 13, 2026Filed Jul 15, 2026 | Borie Dominique ChristianChief Medical Officer | Grant Or AwardDirect | 31,500 | $0 | $0 | Form 4 ↗ |